Full Text View
Tabular View
Study Results
Related Studies
A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder
This study has been completed.
Study NCT00391222   Information provided by Janssen Pharmaceutica N.V., Belgium

First Received on October 20, 2006.   Last Updated on May 19, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bipolar Disorder
More general conditions related to this trial
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders
Interventions listed in this trial
Olanzapine
Placebo
Additional drug interventions recognized in this trial
Risperidone
More general drug interventions related to this trial
Antiemetics
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Janssen Pharmaceutica N.V., Belgium


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services